Review Article
Extent of resection in breast conserving surgery after neoadjuvant chemotherapy: a literature review
Translational Breast Cancer Research
2026;
7:
15
.
(30 April 2026)
Review Article
Magnetic resonance imaging in breast cancer management: current applications, limitations, and future directions
Translational Breast Cancer Research
2026;
7:
14
.
(30 April 2026)
Original Article
The efficacy and safety of metronomic vinorelbine combined with anlotinib in HER2-negative advanced breast cancer: a prospective, single-arm clinical study
Translational Breast Cancer Research
2026;
7:
13
.
(30 April 2026)
Original Article
Efficacy and safety of T-DXd in patients with HER2-positive and HER2-low metastatic breast cancer: a real-world study
Translational Breast Cancer Research
2026;
7:
12
.
(30 April 2026)
Original Article
Datopotamab deruxtecan in Chinese patients with heavily pretreated advanced or metastatic triple-negative breast cancer in the phase I/II TROPION-PanTumor02 study
Translational Breast Cancer Research
2026;
7:
11
.
(30 April 2026)
Editorial Commentary
CDK4/6 inhibitors for premenopausal women with hormone receptor-positive/HER2-negative breast cancer; insight from Young-PEARL
Translational Breast Cancer Research
2026;
7:
10
.
(31 January 2026)
Expert Consensus
Chinese expert consensus on endocrine therapy for breast cancer (2026 edition)
Translational Breast Cancer Research
2026;
7:
9
.
(31 January 2026)
Review Article
Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review
Translational Breast Cancer Research
2026;
7:
8
.
(31 January 2026)
Review Article
BRCA and CDK4/6: allies or antagonists?—efficacy of CDK4/6 inhibitors in HR+/HER2− breast cancer with germline BRCA1/2 mutations: a narrative review
Translational Breast Cancer Research
2026;
7:
7
.
(31 January 2026)
Original Article
The preliminary study on the effect of PSEN1 on the proliferation and invasion of breast cancer cells
Translational Breast Cancer Research
2026;
7:
6
.
(31 January 2026)
Original Article
Prognostic value of RecurIndex in differentiating HER2-low from HER2-negative early-stage breast cancer: a comprehensive clinicopathologic and molecular analysis in Chinese patients
Translational Breast Cancer Research
2026;
7:
5
.
(31 January 2026)
Original Article
Social inequalities in survival among women with breast cancer in southeastern Brazil: a retrospective cohort study
Translational Breast Cancer Research
2026;
7:
4
.
(31 January 2026)
Original Article
Comparison of male breast cancer in China and the US: a real-world cohort study
Translational Breast Cancer Research
2026;
7:
3
.
(31 January 2026)
Original Article
Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China
Translational Breast Cancer Research
2026;
7:
2
.
(31 January 2026)
Original Article
Eligibility for adjuvant CDK4/6 inhibitors in HR+/HER2− early breast cancer: insights from a large cohort in central south China
Translational Breast Cancer Research
2026;
7:
1
.
(31 January 2026)
Editorial Commentary
Axillary management in patients with sentinel lymph node micrometastases following neoadjuvant systemic therapy: a call for de-escalation
Translational Breast Cancer Research
2025;
6:
41
.
(30 October 2025)
Editorial Commentary
Methodological considerations in predicting axillary residual disease using imaging features
Translational Breast Cancer Research
2025;
6:
40
.
(30 October 2025)
Editorial Commentary
Could circulating tumor cells explain why breast conservation improves survival despite higher locoregional recurrence?
Translational Breast Cancer Research
2025;
6:
39
.
(30 October 2025)
Editorial Commentary
TARGIT-IORT in early breast cancer—real world evidence for a risk-adapted approach
Translational Breast Cancer Research
2025;
6:
38
.
(30 October 2025)
Review Article
CHEK2 variants, breast cancer, and implications for management: a narrative review
Translational Breast Cancer Research
2025;
6:
37
.
(30 October 2025)
Review Article
Precision diagnosis and treatment of PI3K/AKT/PTEN signaling pathway in HR-positive advanced breast cancer: perspectives from Chinese experts
Translational Breast Cancer Research
2025;
6:
36
.
(30 October 2025)
Review Article
Organoids in breast cancer translational research: intersection of technologies
Translational Breast Cancer Research
2025;
6:
35
.
(30 October 2025)
Original Article
Patient outcomes and clinician perspectives following one year of ad hoc implementation of neoadjuvant endocrine therapy in early breast cancer
Translational Breast Cancer Research
2025;
6:
34
.
(30 October 2025)
Original Article
Predictive potential of hepatocyte growth factor and bone morphogenetic proteins in lymphatic metastasis of breast cancer
Translational Breast Cancer Research
2025;
6:
33
.
(30 October 2025)
Original Article
The impact and mechanisms of CRIP2 on the biological behavior of triple-negative breast cancer cells
Translational Breast Cancer Research
2025;
6:
32
.
(30 October 2025)